Boston Scientific Corporation engages in the development, manufacture, and marketing of medical devices that are used in interventional medical specialties. The company's products are offered by two groups, Cardiovascular and Endosurgery. The Cardiovascular organization provides products and technologies for use in interventional cardiology, peripheral interventions, vascular surgery, electrophysiology, and neurovascular procedures. The Endosurgery organization provides products and technologies for use in oncology, endoscopy, urology, and gynecology procedures. In addition, the company operates in the neuromodulation market. It provides products for the treatment of auditory disorders and chronic pain. The company’s less-invasive medical products are used for enlarging narrowed blood vessels to prevent heart attack and stroke; clearing passages blocked by plaque to restore blood flow; opening obstructions and bringing relief to patients suffering from various forms of cancer; performing biopsies and intravascular ultrasounds; mapping electrical problems in the heart; placing filters to prevent blood clots from reaching the lungs, heart, or brain; treating urological, renal, pulmonary, neurovascular, and gastrointestinal diseases; and modulating nerve activity to treat deafness and chronic pain. The company markets its products through direct sales force, and a network of distributors and dealers. Boston Scientific Corp. has a collaboration agreement with Affinergy, Inc. to investigate new coatings for cardiovascular stents. The company was founded by John E. Abele and Peter M. Nicholas in 1979. Boston Scientific Corp. is headquartered in ssachusetts.